Agenus (NASDAQ:AGEN) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Agenus (NASDAQ:AGEN) in a report issued on Tuesday morning, Benzinga reports. The firm currently has a $40.00 price objective on the biotechnology company’s stock.

Several other analysts also recently commented on the company. B. Riley lowered their price objective on Agenus from $120.00 to $100.00 and set a buy rating for the company in a research note on Monday, March 18th. StockNews.com began coverage on Agenus in a research note on Wednesday, April 17th. They set a hold rating on the stock.

Agenus Stock Down 7.3 %

NASDAQ AGEN opened at $12.01 on Tuesday. The business has a 50 day moving average price of $10.78 and a 200-day moving average price of $13.24. Agenus has a 52 week low of $4.78 and a 52 week high of $42.60. The company has a market cap of $243.56 million, a price-to-earnings ratio of -0.85 and a beta of 1.25.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The firm had revenue of $83.80 million for the quarter, compared to analysts’ expectations of $54.21 million. On average, equities research analysts anticipate that Agenus will post -8.21 earnings per share for the current year.

Insider Activity at Agenus

In other Agenus news, insider Garo H. Armen acquired 25,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were acquired at an average price of $13.00 per share, with a total value of $325,000.00. Following the completion of the transaction, the insider now owns 31,298 shares in the company, valued at $406,874. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in Agenus in the third quarter valued at approximately $36,000. PCG Wealth Advisors LLC lifted its position in shares of Agenus by 65.7% during the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 18,850 shares during the last quarter. RPO LLC purchased a new position in shares of Agenus during the 4th quarter valued at $43,000. Lindbrook Capital LLC grew its stake in shares of Agenus by 38.8% during the 3rd quarter. Lindbrook Capital LLC now owns 52,535 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 14,674 shares during the period. Finally, First Command Advisory Services Inc. purchased a new stake in Agenus in the 3rd quarter worth about $80,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.